Pancreatic cancer: yesterday, today and tomorrow-Reference-Cited by-同舟云学术

Pancreatic cancer: yesterday, today and tomorrow

Published:2016-08 Issue:16 Volume:12 Page:1929-1946
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Ansari Daniel¹,Tingstedt Bobby¹,Andersson Bodil¹,Holmquist Fredrik²,Sturesson Christian¹,Williamsson Caroline¹,Sasor Agata³,Borg David⁴,Bauden Monika¹,Andersson Roland¹

Affiliation:

1. Department of Surgery, Clinical Sciences Lund, Lund University & Skåne University Hospital, Lund, Sweden

2. Department of Radiology, Clinical Sciences Lund, Lund University & Skåne University Hospital, Lund, Sweden

3. Department of Pathology, Skåne University Hospital, Lund, Sweden

4. Department of Oncology, Skåne University Hospital, Lund, Sweden

Abstract

Pancreatic cancer is one of our most lethal malignancies. Despite substantial improvements in the survival rates for other major cancer forms, pancreatic cancer survival rates have remained relatively unchanged since the 1960s. Pancreatic cancer is usually detected at an advanced stage and most treatment regimens are ineffective, contributing to the poor overall prognosis. Herein, we review the current understanding of pancreatic cancer, focusing on central aspects of disease management from radiology, surgery and pathology to oncology.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2016-0010

Reference135 articles.

1. Codivilla A. Rendiconto statistico della sezione chirurgica dell'ospedale di Imola. Imola, Italy (1898).

2. Contributions to the Surgery of the Bile Passages, Especially of the Common Bile-Duct

Cited by 294 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of KDM5B participates in immune microenvironment remodeling in pancreatic cancer by inducing STING expression;Cytokine;2024-03

2. Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection;Surgical Oncology Insight;2024-02

3. Evaluation of the cytotoxic and immunomodulatory effects of sonodynamic therapy in human pancreatic cancer spheroids;Journal of Photochemistry and Photobiology B: Biology;2024-02

4. Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma;Frontiers in Immunology;2024-01-30

5. Epigenetic priming targets tumor heterogeneity to shift transcriptomic phenotype of pancreatic ductal adenocarcinoma towards a Vitamin D susceptible state;Cell Death & Disease;2024-01-26